Tanja Čufer

13.0k total citations · 2 hit papers
145 papers, 6.9k citations indexed

About

Tanja Čufer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Tanja Čufer has authored 145 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 56 papers in Pulmonary and Respiratory Medicine and 53 papers in Cancer Research. Recurrent topics in Tanja Čufer's work include Lung Cancer Treatments and Mutations (37 papers), Cancer Treatment and Pharmacology (28 papers) and Lung Cancer Research Studies (27 papers). Tanja Čufer is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Cancer Treatment and Pharmacology (28 papers) and Lung Cancer Research Studies (27 papers). Tanja Čufer collaborates with scholars based in Slovenia, Belgium and United States. Tanja Čufer's co-authors include Sanjay Popat, Keith M. Kerr, Raffaele Califano, Matteo Giaj Levra, Solange Peters, Silvia Novello, Suresh Senan, Martin Reck, Simon Ekman and Fabrice Barlési and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Tanja Čufer

142 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2016 1.9k citations Tanja Čufer et al. Annals of Oncology profile →
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

2009 504 citations Gϋnter von Minckwitz, Marcus Schmidt et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tanja Čufer Slovenia	36	4.4k	3.2k	2.0k	1.4k	699	145	6.9k
Joyce O’Shaughnessy United States	40	7.0k 1.6×	2.8k 0.9×	3.1k 1.5×	2.1k 1.5×	739 1.1×	240	9.6k
Étienne Brain France	43	5.4k 1.2×	2.9k 0.9×	2.9k 1.4×	1.1k 0.7×	573 0.8×	220	8.4k
Sergei Tjulandin Russia	34	5.3k 1.2×	3.4k 1.1×	1.5k 0.8×	1.4k 1.0×	625 0.9×	175	8.6k
Alessandro Morabito Italy	40	4.8k 1.1×	3.4k 1.1×	1.7k 0.8×	1.7k 1.2×	487 0.7×	217	7.2k
Eva Ciruelos Spain	32	5.3k 1.2×	2.3k 0.7×	2.4k 1.2×	1.5k 1.1×	1.5k 2.1×	208	7.1k
Edward S. Kim United States	52	5.2k 1.2×	5.3k 1.7×	1.9k 0.9×	2.9k 2.0×	665 1.0×	216	9.8k
Joohyuk Sohn South Korea	44	7.9k 1.8×	5.6k 1.8×	3.3k 1.6×	1.8k 1.3×	650 0.9×	303	10.9k
Michael L. Cher United States	42	2.0k 0.5×	2.5k 0.8×	1.6k 0.8×	1.9k 1.3×	437 0.6×	165	5.5k
Philip Bonomi United States	42	4.9k 1.1×	4.4k 1.4×	978 0.5×	2.1k 1.5×	485 0.7×	241	8.0k
Arlene Chan Australia	30	5.4k 1.2×	2.3k 0.7×	1.7k 0.8×	1.8k 1.2×	1.1k 1.6×	144	6.8k

Countries citing papers authored by Tanja Čufer

Since Specialization

Citations

This map shows the geographic impact of Tanja Čufer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tanja Čufer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tanja Čufer more than expected).

Fields of papers citing papers by Tanja Čufer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tanja Čufer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tanja Čufer. The network helps show where Tanja Čufer may publish in the future.

Co-authorship network of co-authors of Tanja Čufer

This figure shows the co-authorship network connecting the top 25 collaborators of Tanja Čufer. A scholar is included among the top collaborators of Tanja Čufer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tanja Čufer. Tanja Čufer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Petronijević, Milan, et al.. (2025). Outcomes in Patients with Non-Small-Cell Lung Cancer with Brain Metastases: A Real-World Data Study from a Resource-Limited Country. Cancers. 17(10). 1603–1603.

Morfouace, Marie, Daniel Schulz, Nils Eling, et al.. (2023). 2266P IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort. Annals of Oncology. 34. S1164–S1164. 2 indexed citations

Čufer, Tanja, et al.. (2023). Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer. Frontiers in Oncology. 13. 1182748–1182748. 7 indexed citations

Horgan, Denis, Tanja Čufer, Francesco Gatto, et al.. (2022). Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring. Healthcare. 10(9). 1714–1714. 21 indexed citations

Čufer, Tanja, et al.. (2022). Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer. Radiology and Oncology. 56(3). 346–354. 8 indexed citations

Čufer, Tanja, et al.. (2018). Pomen mutacije gena receptorja za epidermalni rastni dejavnik za zdravljenje nedrobnoceličnega raka pljuč. SHILAP Revista de lepidopterología. 1 indexed citations

Čufer, Tanja, et al.. (2018). Febrilna nevtropenija in nevtropenija višje stopnje ob adjuvantnem zdravljenju nedrobnoceličnega raka pljuč v vsakodnevni praksi. SHILAP Revista de lepidopterología. 1 indexed citations

Čufer, Tanja, et al.. (2018). 154P CNS response to osimertinib in patients with EGFR mutated lung adenocarcinoma: Real world data. Journal of Thoracic Oncology. 13(4). S92–S93. 3 indexed citations

Sonnenblick, Amir, Dominique Agbor‐Tarh, Ian Bradbury, et al.. (2017). Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. Journal of Clinical Oncology. 35(13). 1421–1429. 106 indexed citations

10.

Grabnar, Iztok, et al.. (2015). Febrile neutropenia in chemotherapy treated small-cell lung cancer patients. Radiology and Oncology. 49(2). 173–180. 9 indexed citations

11.

Ramlau, Rodryg, Tanja Čufer, Rafał Dziadziuszko, et al.. (2015). Epidermal Growth Factor Receptor Mutation-PositiveNon-Small-Cell Lung Cancer in the Real-World Setting in CentralEurope The INSIGHT Study. Journal of Thoracic Oncology. 1 indexed citations

12.

Zwitter, Matjaž, et al.. (2014). Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiology and Oncology. 48(2). 173–183. 46 indexed citations

13.

Takač, Iztok, et al.. (2011). The role of the urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer. SHILAP Revista de lepidopterología. 1 indexed citations

14.

Minckwitz, Gϋnter von, Kathrin Schwedler, Marcus Schmidt, et al.. (2011). Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer. 47(15). 2273–2281. 141 indexed citations

15.

Ovčariček, Tanja, Nadja Triller, Aleksander Sadikov, & Tanja Čufer. (2010). Prognostic value of C-reactive protein and other classical factors in patients with advanced non-small cell lung carcinoma treated in routine clinical practice. SHILAP Revista de lepidopterología. 79(10). 669–676. 1 indexed citations

16.

Pagani, Olivia, Elżbieta Senkus, WC Wood, et al.. (2010). International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?. JNCI Journal of the National Cancer Institute. 102(7). 456–463. 292 indexed citations

17.

Paridaens, Robert, Luc Dirix, L.V.A.M. Beex, et al.. (2008). Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology. 26(30). 4883–4890. 228 indexed citations

18.

Čufer, Tanja. (2004). Clinical utility of serine proteases in breast cancer. DiRROS repository (University of Maribor). 2 indexed citations

19.

Paridaens, Robert, Luc Dirix, Caroline Lohrisch, et al.. (2003). Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of Oncology. 14(9). 1391–1398. 172 indexed citations

20.

Borštnar, Simona, Ivan Vrhovec, Branka Svetic, & Tanja Čufer. (2002). Prognostic Value of the Urokinase-Type Plasminogen Activator, and its Inhibitors and Receptor in Breast Cancer Patients. Clinical Breast Cancer. 3(2). 138–146. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact